Sanofi Reports Success in Trial for Rare Infant Genetic Disease Treatment
Paris, Tuesday, 30 June 2026.
Sanofi’s latest clinical trial successfully kept infants with a rare, fatal genetic disease alive and ventilator-free for a year, proving highly effective with no serious side effects.
A Milestone in Pediatric Rare Disease Therapy
On June 29 and 30, 2026, French biopharmaceutical giant Sanofi (NASDAQ: SNY) announced highly positive results from its Phase 3 Baby-COMET clinical trial (NCT04910776) [1]. The trial evaluated Nexviazyme (avalglucosidase alfa) in infants aged 0 to 6 months suffering from infantile-onset Pompe disease (IOPD) [1]. This single-arm, open-label study, which enrolled 17 participants who received intravenous doses of 40 mg/kg every other week, successfully met its primary endpoint [1]. Specifically, the treatment demonstrated that the infants remained alive and free of invasive ventilation at the 52-week mark, marking a significant clinical success for the enzyme replacement therapy [1].
Understanding Infantile-Onset Pompe Disease
Infantile-onset Pompe disease is an exceptionally rare, progressive, and devastating genetic neuromuscular condition [1]. It is caused by a deficiency in the acid alpha-glucosidase (GAA) enzyme, which leads to toxic glycogen accumulation in muscle tissues [1][GPT]. Dr. Priya S. Kishnani, the Medical Director of the YT and Alice Chen Pediatrics Genetics and Genomics Center at Duke University Medical Center, emphasized that the condition presents within the first days or weeks of life, making early intervention critical [1]. Dr. Kishnani noted that the Baby-COMET study demonstrates the clear potential of avalglucosidase alfa to support ventilator-free survival, while also yielding highly encouraging cardiac and motor outcomes for these vulnerable patients [1].
Safety Outcomes and Tolerability
Beyond efficacy, the safety profile of Nexviazyme in this sensitive patient population was highly reassuring. The trial reported zero serious treatment-related adverse events, zero deaths, and zero treatment discontinuations [1]. Infusion-associated reactions were documented in 29.4% of the participants, all of which were deemed manageable [1]. Out of the 17 infants enrolled in the trial, this safety profile indicates that approximately 4.998 patients experienced these mild to moderate reactions, allowing the remaining majority of the cohort to undergo therapy without such events [1].
Expanding the Therapeutic Footprint
The success of the trial offers a vital lifeline to families dealing with a disease that historically carries a rapid and fatal prognosis without intervention [1][GPT]. Christopher Corsico, the Global Head of Development at Sanofi, stated that these positive results provide the potential to expand the clinical access of Nexviazyme to more patients in the earliest months of their lives [1]. By addressing the critical therapeutic gap in the first half-year of infancy, Sanofi aims to establish its therapy as a foundational standard of care for newly diagnosed infants [1][GPT].
Market and Regulatory Path Forward
From a strategic perspective, the positive clinical data secures the long-term commercial outlook for Sanofi’s Pompe disease franchise, strengthening its competitive moat in the high-margin rare disease and enzyme replacement therapy markets [GPT]. Sanofi is scheduled to present the comprehensive data from the Baby-COMET study on July 8, 2026, at the 19th International Congress on Neuromuscular Diseases in Florence, Italy [1]. Following the presentation, the pharmaceutical company plans to submit a regulatory label extension application to the U.S. Food and Drug Administration (FDA) in the second half of 2026 [1].
Managing Pipeline Risks
While the clinical milestone represents a major step forward, the pending regulatory approvals by authorities such as the FDA and the European Medicines Agency (EMA) remain subject to rigorous review [1]. Sanofi’s forward-looking projections regarding the commercialization and approval of Nexviazyme are governed by the Private Securities Litigation Reform Act of 1995 [1]. These plans are subject to various industry risks and uncertainties, as outlined in Sanofi’s annual report on Form 20-F for the fiscal year ended December 31, 2025 [1]. Nevertheless, the success of the Phase 3 trial substantially mitigates pipeline development risks for the company’s rare disease portfolio [GPT].